Tempest Therapeutics, Inc. (NASDAQ:TPST) Financings

Tempest Therapeutics, Inc.

Financings

RaiseDate
Private placement of shares of common stock (or pre-funded warrants) with series C and series D warrants
Announced: about US$2.5M · US$0.805 a share · Warrants at US$0.805 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and other general corporate purposes
Sep 11, 2026
Strategic investment of investment commitment
Update: strategic investment
Buyers: Factor Bioscience Inc. (investment commitment / financing support)
Use of proceeds: Together with existing cash, expected to provide a runway to mid-2027 and potentially through key data milestones
Feb 4, 2026
Registered direct offering of shares of common stock (or common stock equivalents) with concurrent private placement of short-term unregistered warran
Closed: US$4.25M raised · US$3.625 a share · Warrants at US$3.5 for 18 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Primarily working capital and general corporate purposes
Nov 26, 2025
Registered direct offering of shares of common stock (or common stock equivalents)
Announced: about US$4.6M · US$6.25 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Buyers: single institutional investor (739,000 shares of common stock (or common stock equivalents))
Use of proceeds: Supporting the previously announced strategic alternative process, working capital and general corporate purposes
Jun 11, 2025

Read by 6ix AI from the company's releases